EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk.

Katarzyna Styczkiewicz, Paweł Plata, Kinga Polityńska

OncoReview · 30.03.2026 · 15 (4(60)) · 62-66

DOI: 10.24292/01.or.164222226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift OncoReview, online erschienen am 30.03.2026. Verfasst von Katarzyna Styczkiewicz und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced chronological age should not automatically lead to patients' disqualification from cancer therapies, which have the potential to prolong life. When functional status is prioritized over metric age, even octogenarians with significant comorbidities can have access to even modern oncological therapies. We present the case of an 88-year-old patient with high cardiovascular risk, who was enrolled in adjuvant nivolumab therapy due to melanoma recurrence. In 2021, the patient was diagnosed with malignant melanoma of the lumbar region at stage T2a, which was initially successfully surgically treated. After 3 years, regional melanoma recurrence in the axillary lymph nodes was detected (stage III, BRA F-) indicating the necessity for systemic treatment. During cardiological consultation before planned immunotherapy, severe aortic stenosis was confirmed. The patient finally was qualified for nivolumab therapy under cardio-oncological supervision, despite advanced age and high cardiovascular risk. After 5 courses of immunotherapy, no recurrence was found on follow-up computed tomography, and no cardiac status worsening was observed. This case demonstrates that advanced age combined even with high cardiovascular risk should no longer be a barrier to immunotherapy under an appropriate monitoring protocol preserving the safety and continuity of oncological treatment.

Zitieren

APA

Styczkiewicz, K., Plata, P., & Polityńska, K. (2026). Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk. OncoReview, 15(4(60)), 62-66. https://doi.org/10.24292/01.or.164222226

Vancouver

Styczkiewicz K, Plata P, Polityńska K. Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk. OncoReview. 2026;15(4(60)):62-66. doi:10.24292/01.or.164222226

BibTeX
@article{Styczkiewicz2026,
  author = {Styczkiewicz, Katarzyna and Plata, Paweł and Polityńska, Kinga},
  title = {Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk},
  journal = {OncoReview},
  year = {2026},
  volume = {15},
  number = {4(60)},
  pages = {62--66},
  doi = {10.24292/01.or.164222226}
}
Kostenlos starten →